• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Digital Health Could Serve As Valuable Asset for Pharma Industry

by HITC Staff 03/16/2018 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Patient Engagement_Pharma Marketing to Physicians

Digital health is proving to be a valuable asset for the pharma industry, as it points to a more streamlined and more cost-effective drug development process, according to GlobalData, a leading data and analytics company.

Recent years have seen a large increase in investment towards digital health – a multifaceted segment of the industry that can combine software-based therapies into various aspects of the drug development process.

Rahael Maladwala, Healthcare Analyst at GlobalData, notes: “GlaxoSmithKline recently completed a $43m deal allowing it use Exscientia’s AI platform in the drug discovery process. The digital startup will attempt to use machine learning and specifically designed algorithms to identify molecules in the body that could be potential drug targets, by predicting how they behave under certain conditions. If this method can successfully identify new drug targets, it would reduce the financial burden of pharmaceutical companies for R&D.” 

Other uses of technology in healthcare include improvements to the cost-effectiveness of clinical trials. Novartis has launched the first app-based study in multiple sclerosis that allows patients to log symptoms in real time. Meanwhile, Takeda and Lundbeck have begun using apps to monitor patients suffering from depression and how they respond to their prescribed therapies. Wearable technology is also being tested in indications that involve abnormal motor movement, such as Parkinson’s disease, multiple sclerosis, and epilepsy. The most notable examples of these include Empatica’s seizure alerting wristband, and Great Lakes NeuroTechnologies’ Kinesia 360, a sensor-smartphone app combination used to monitor Parkinson’s symptoms.

Maladwala continues: “Moving forward, this technology can be used to link clinical outcomes to real-world patient behavior, and pharma companies can develop novel endpoints – for example related to compliance in a real-world setting – that would not be possible to test in a standard clinical trial.

“As digital health is integrated more and more into the traditional drug development process, there will be challenges that need to be overcome. However, the current trends in this area all point to a more cost-effective drug development process. At a time when payer pressure aims to reduce the financial burden of healthcare for patients, this may prove invaluable for the pharma industry.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Pharma

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

Digital Health Funding Q3 2025: Choppy Undercurrents Beneath a Steady Surface

Featured Interview

ConcertAI VP Shares View on AI Hallucinations and the Fabricated Data Crisis in Scientific Publishing

Most-Read

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

KLAS Report: Epic's Native Ambient Speech Tool Reshapes Customer AI Strategies

KLAS Report: Epic’s Native Ambient Speech Tool Reshapes Customer AI Strategies

Epic Unveils MyChart Central and New APIs to Advance Interoperability at Open@Epic

Epic Outlines Roadmap for Next-Generation Data Sharing at Open@Epic

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

Oracle Confirms Layoffs in Kansas City

Oracle Confirms Layoffs in Kansas City

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Optain Health Secures $26M to Advance AI-Powered Retinal Screening

Optain Health Secures $26M for AI-Powered Retinal Screening

Sutter Health and Epic Launch "Sutter Sync" to Optimize Remote Chronic Care

Sutter Health and Epic Launch “Sutter Sync” to Optimize Remote Chronic Care

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |